What diseases does Upadacitinib tablets mainly treat and its clinical applications?

Upadacitinib is a selective Janus kinase 1 (JAK1) inhibitor and is a small molecule targeted oral drug. It interferes with the JAK-STAT signaling pathway, thereby reducing the release of inflammatory factors and inflammatory response. This drug is widely used to treat a variety of chronic autoimmune diseases, especially for patients who have insufficient response or intolerance to conventional treatments. It is currently one of the important innovative drugs in the field of rheumatism and immunity.

Upatinib was first approved for the treatment of moderately to severely active rheumatoid arthritis (RA). It is particularly suitable for patients who have had an inadequate response to methotrexate or other traditional antirheumatic drugs (csDMARDs). Clinical studies have shown that upadatinib can significantly reduce joint swelling and pain, improve functional impairment, and performs well in delaying joint structural destruction. Compared with some traditional treatments, it works faster and has better compliance.

In addition, upadatinib is also widely used to treat psoriatic arthritis (PsA), ankylosing spondylitis (AS), atopic dermatitis (AD) and other diseases. Especially in the treatment of moderate to severe atopic dermatitis, upadatinib shows strong anti-itching and skin lesion improvement effects. It is suitable for patients with long-term recurring attacks and poor efficacy of external medications, filling the gap in the treatment of some refractory diseases.

In clinical practice, the use of upadatinib should follow the guidance of doctors and undergo individualized assessment based on the patient's condition, comorbidities, and tolerance. Because it may affect immune function, screening for tuberculosis, hepatitis B and other infections is required before treatment, and blood routine, liver function and other indicators are regularly monitored during medication to ensure medication safety. Overall, upadatinib has become a new option for the treatment of various autoimmune diseases, providing patients with a more flexible and effective treatment path.

Reference materials:https://www.drugs.com/